A pilot trial of the daily intraperitoneal administration of recombinant interleukin-2

M. Markman; N. Iannotti; T. Hakes; B. Reichman; S. Rubin; W. Jones; W. Hoskins; J. L. Lewis

A pilot trial of the daily intraperitoneal administration of recombinant interleukin-2

M. Markman
, N. Iannotti
, T. Hakes
, B. Reichman
, S. Rubin
, W. Jones
, W. Hoskins
, J. L. Lewis

Surgery

Memorial Sloan-Kettering Cancer Center

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

In an effort to develop a rational and practical intraperitoneal (i.p.) recombinant interleukin-2 (rIL-2) program that could be explored in future studies of combination i.p. biological therapy, a pilot trial of single-agent rIL-2 delivered i.p. as a single daily dose on a 5-times-weekly schedule was initiated. With a daily x 5 dose of 8 x 10⁵ units/m² rIL-2 (Ro 23-6019) only minimal systemic and local toxicity was encountered. This dose is recommended for future trials of combination i.p. biological therapy employing a daily x 5 schedule.

Original language	English
Pages (from-to)	44-46
Number of pages	3
Journal	Regional Cancer Treatment
Volume	3
Issue number	1
State	Published - 1990

Cite this

@article{9dcee5af2cd2461a9b4e3e7d7fe0c6f9,

title = "A pilot trial of the daily intraperitoneal administration of recombinant interleukin-2",

abstract = "In an effort to develop a rational and practical intraperitoneal (i.p.) recombinant interleukin-2 (rIL-2) program that could be explored in future studies of combination i.p. biological therapy, a pilot trial of single-agent rIL-2 delivered i.p. as a single daily dose on a 5-times-weekly schedule was initiated. With a daily x 5 dose of 8 x 105 units/m2 rIL-2 (Ro 23-6019) only minimal systemic and local toxicity was encountered. This dose is recommended for future trials of combination i.p. biological therapy employing a daily x 5 schedule.",

author = "M. Markman and N. Iannotti and T. Hakes and B. Reichman and S. Rubin and W. Jones and W. Hoskins and Lewis, \{J. L.\}",

year = "1990",

language = "English",

volume = "3",

pages = "44--46",

journal = "Regional Cancer Treatment",

issn = "0935-0411",

publisher = "Springer Verlag",

number = "1",

}

TY - JOUR

T1 - A pilot trial of the daily intraperitoneal administration of recombinant interleukin-2

AU - Markman, M.

AU - Iannotti, N.

AU - Hakes, T.

AU - Reichman, B.

AU - Rubin, S.

AU - Jones, W.

AU - Hoskins, W.

AU - Lewis, J. L.

PY - 1990

Y1 - 1990

N2 - In an effort to develop a rational and practical intraperitoneal (i.p.) recombinant interleukin-2 (rIL-2) program that could be explored in future studies of combination i.p. biological therapy, a pilot trial of single-agent rIL-2 delivered i.p. as a single daily dose on a 5-times-weekly schedule was initiated. With a daily x 5 dose of 8 x 105 units/m2 rIL-2 (Ro 23-6019) only minimal systemic and local toxicity was encountered. This dose is recommended for future trials of combination i.p. biological therapy employing a daily x 5 schedule.

AB - In an effort to develop a rational and practical intraperitoneal (i.p.) recombinant interleukin-2 (rIL-2) program that could be explored in future studies of combination i.p. biological therapy, a pilot trial of single-agent rIL-2 delivered i.p. as a single daily dose on a 5-times-weekly schedule was initiated. With a daily x 5 dose of 8 x 105 units/m2 rIL-2 (Ro 23-6019) only minimal systemic and local toxicity was encountered. This dose is recommended for future trials of combination i.p. biological therapy employing a daily x 5 schedule.

UR - https://www.scopus.com/pages/publications/0025185516

M3 - Article

AN - SCOPUS:0025185516

SN - 0935-0411

VL - 3

SP - 44

EP - 46

JO - Regional Cancer Treatment

JF - Regional Cancer Treatment

IS - 1

ER -

A pilot trial of the daily intraperitoneal administration of recombinant interleukin-2

Abstract

Other files and links

Fingerprint

Cite this